Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Aurisco Pharmaceutical Co., Ltd.: API, pharmaceutical intermediates, and preparation factory

Release time：2024-09-24 20:27:32 Source：DuHao

Contact Us Today

Tel : +86-0576-83177319

Email: net.fei@163.com

Address: Badu Industrial Park Zone, Tiantai, Zhejiang Province, China

Established in 1998, Aurisco Pharmaceutical Co., Ltd. has emerged as a pioneering force in the pharmaceutical industry, dedicated to the research, manufacturing, and marketing of specialty Active Pharmaceutical Ingredients (APIs), finished dosage forms (FDF), and contract manufacturing organization (CMO) services. With its headquarters situated in Badu Industrial Park, Tiantai County, Zhejiang Province, Aurisco operates a robust network of subsidiaries across the globe, including locations in the USA, Portugal, India, Brazil, Yangzhou, Hangzhou, and Tianjing. This expansive reach underlines Aurisco's commitment to delivering high-quality pharmaceutical products and services worldwide.

With over 20 years of experience in the pharmaceutical sector, Aurisco has established itself as a leader in complex synthesis, synthetic biology, and photochemistry. The company’s dedication to technological innovation positions it as a long-term partner for renowned pharmaceutical companies globally. Aurisco’s comprehensive quality assurance system, coupled with ample production capacity and a global sales network, enables it to meet the diverse needs of its customers effectively.

Regulatory Compliance and Quality Assurance

Aurisco takes pride in its impeccable compliance record, evidenced by its zero 483 forms and zero recalls. The company has successfully achieved various regulatory approvals, including those from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The timeline of its certifications reflects a consistent commitment to meeting stringent international standards, with approvals spanning from CFDA in 2007 to recent certifications from the FDA and KFDA in 2023.

Product Portfolio

Aurisco’s product range includes APIs, FDF, and CRO & CDMO services, with a notable focus on specialty APIs for therapeutic areas such as respiratory, cardiovascular, anti-infective, and central nervous system disorders. Key products include flumethasone, fluticasone propionate, eplerenone, tenofovir, and pregabalin, which are primarily marketed to large international pharmaceutical companies.

In 2023, the company marked a significant milestone by registering its first preparation product, Dydrogesterone Tablets, becoming the first manufacturer of this generic drug in China. This achievement underscores Aurisco’s strategy to integrate API production with downstream preparation manufacturing, further enhancing its market position.

Financial Performance

Aurisco has demonstrated impressive financial growth, with a total operating income of RMB 731 million in the first half of 2024, reflecting a year-on-year increase of 32.21%. The operating profit surged to RMB 218 million, a remarkable increase of 84.44%. This performance is attributed to the company’s ongoing commitment to expanding its core API business and entering new market segments.

Future Outlook

Looking ahead, Aurisco plans to capitalize on its technical and market advantages by expanding its export of specialty APIs, broadening its product categories, and enhancing its preparation market presence. The construction of new facilities, including an annual production line for specialty APIs and an anti-tumor preparation plant, positions Aurisco for continued growth and innovation. The application of synthetic biology in product development is also expected to yield innovative breakthroughs, ensuring that Aurisco remains at the forefront of pharmaceutical advancements.

In summary, Aurisco Pharmaceutical Co., Ltd. stands as a beacon of excellence in the pharmaceutical industry, driven by a commitment to quality, innovation, and customer satisfaction. With a robust operational framework and a clear strategic vision, Aurisco is well-equipped to navigate the challenges of the global pharmaceutical landscape while continuing to deliver high-quality solutions to its partners and clients.

DuHao Net